Key regions: France, Europe, United Kingdom, Brazil, India
The demand for oncology drugs in Qatar has been steadily increasing over the past few years.
Customer preferences: Cancer is one of the leading causes of death worldwide, and Qatar is no exception. With an aging population and an increase in cancer cases, the demand for oncology drugs has been on the rise. Patients in Qatar prefer innovative and effective treatments that can improve their quality of life and increase their chances of survival.
Trends in the market: The oncology drugs market in Qatar has been growing at a steady pace due to a number of factors. Firstly, the government has been investing heavily in healthcare infrastructure, which has led to an increase in the number of hospitals and clinics in the country. This has made it easier for patients to access oncology treatments. Secondly, there has been a rise in the number of cancer cases in Qatar, which has led to an increase in demand for oncology drugs. Thirdly, there has been an increase in the number of oncology drug approvals by the Qatar Food and Drug Authority (QFDA), which has led to more treatment options for patients.
Local special circumstances: The healthcare system in Qatar is heavily subsidized by the government, which means that patients have access to affordable healthcare. The government has also implemented a national cancer screening program, which has helped in the early detection of cancer cases. Additionally, Qatar has a high-income population, which means that patients have the financial resources to afford expensive oncology treatments.
Underlying macroeconomic factors: Qatar is one of the wealthiest countries in the world, with a high GDP per capita. This has led to an increase in healthcare spending, which has benefited the oncology drugs market. Additionally, Qatar has a high prevalence of risk factors for cancer, such as smoking and obesity, which has led to an increase in cancer cases. The government has recognized this and has implemented measures to reduce these risk factors. Finally, Qatar is a hub for medical tourism, which has led to an increase in demand for oncology treatments from patients from neighboring countries.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
